Added to YB: 2024-02-14
Pitch date: 2024-02-12
ANVS [bullish]
Annovis Bio, Inc.
-59.11%
current return
Author Info
Anders Research shares equity research primarily focused on micro/small/mid-cap biotechnology. We follow companies with mechanistically differentiated approaches to large market opportunities, with special focus in neuroscience. Sign up for the newsletter.
Company Info
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration.
Market Cap
$56.0M
Pitch Price
$10.10
Price Target
N/A
Dividend
N/A
EV/EBITDA
N/A
P/E
-0.74
EV/Sales
N/A
Sector
Biotechnology
Category
growth
Annovis: Potentially Encouraging Anecdotes, Weighing Phase 3 Parkinson's Prospects
ANVS nears Ph3 PD trial results for buntanetap. Anecdotes from 21 patients suggest efficacy, 38% had symptom relief, promising for 20mg cohort. +ve outcome could mean 5-10x return in 6-12mo given neuro mkt size & AD readthrough, despite cash concerns & PR issues.
Read full article (16 min)